90th Annual Meeting Sponsored Satellite Education Symposium Program
(Non-CME)

Thursday, September 30th, 12:30-1:00pm EDT
Insights and Information for Impact in the Treatment of Hypothyroidism 
Captain Thanh D. Hoang, DO, FACP, a national leader in the treatment of hypothyroidism, provides a non-CME disease education symposium surveying epidemiological, etiological, and clinical aspects of the disease, including suboptimal response to and patient dissatisfaction with LT4 monotherapy, the importance of patient-reported outcomes to evaluate treatment response, and the role of combination therapy in treatment.

Friday, October 1st, 10:00-11:00am EDT
LENVIMA®: A First-Line Treatment for Patients with Locally Recurrent, or Metastatic, Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer 
This symposium will educate HCPs on LENVIMA as a 1L option for treatment of RAI-R DTC including an overview of the SELECT trial and efficacy data as well as safety profiles and strategies to recognize, monitor, and manage common adverse reactions (ARs) that may occur with LENVIMA. In addition, an overview of the disease state and prognosis will be provided along with a review of treatment paths, active surveilling, and selection of appropriate patients for systemic therapy. Attendees will have the opportunity to review patient case studies and engage in discussion regarding the treatment selection process.

Friday, October 1st, 1:00-1:50pm EDT
An Expert Discussion on TEPEZZA® (teprotumumab-trbw) 
You are invited to An Expert Discussion on TEPEZZA with Dr. Raymond S. Douglas and Dr. Terry J. Smith. This 45-minute moderated panel discussion with Q&A will dive into emerging science around the pathophysiology of Thyroid Eye Disease (TED) and pharmacokinetics of TEPEZZA. Clinical practice considerations will be explored, including mechanism of action and efficacy of response upon treatment completion.

Saturday, October 2nd, 9:30-10:00am EDT
Sponsored Educational Symposium: Afirma Genomic Sequencing Classifier & Xpression Atlas: Real-world molecular findings from over 50,000 nodules and impact on clinical management 
In this symposium, Dr. Richard T. Kloos, Executive Medical Director, will highlight recent findings from over 50,000 consecutive Bethesda III-VI Afirma GSC+XA samples and their application to clinical management.

Saturday, October 2nd, 1:00-2:00pm EDT
Updates on Clinical Utility of ThyroSeq® Test for Thyroid Nodules, Cancer, and Pediatric Patients
Course Objectives:
• To provide an update on utility of multi-gene molecular test for personalized management of patients with thyroid nodules
• To discuss a new study validating the performance of multi-gene molecular test in pediatric patients
• To discuss a recently validated ThyroSeq Cancer Risk Classifier (CRC) for assessing risk of recurrence in cytologically malignant nodules and resected cancers.

Sunday, October 3rd, 10am-11:00am EDT
Retevmo® (selpercatinib): A precision-based therapy for certain RET-driven cancers
Focus on Advanced or Metastatic Thyroid Cancer 
Join us to review the clinical data for LIBRETTO-001, examine the efficacy and safety profiles, and explore the dosing, dose modifications, administration, and appropriate testing methods for a biomarker-driven therapy. This program aims to help you identify patients who may be eligible for this treatment option. This program is sponsored by and the speaker is presenting on behalf of Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

NOTE: ATA does not endorse any company, program or service provided by our partners. These education programs are provided for informational purposes and do not reflect the viewpoints of the ATA.